ORBIMED ADVISORS LLC
Q2 2021 13F-HR Detailed Holdings
Net value change ($000)
-808,159
(-7.6%)
New positions
22
Sold out positions
20
Turnover %
10.4%
Sector allocation + QoQ delta (equities-only)
Holdings broken out by other managers reported in the original SEC filing. View aggregated holdings
You are on the SEC detailed breakdown page.
Rows are shown as reported in the filing (including other manager, discretion, and voting authority fields),
and are not merged like the standard holdings view.
Switch to aggregated holdings.
Snapshot: Change Analysis
Compared to Q1 2021
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| XBI | 126,694 | NEW |
| NPCE | 95,452 | NEW |
| JANX | 86,486 | NEW |
| VectivBio Holding AG | 59,738 | NEW |
| Deciphera Pharmaceuticals, Inc. | 58,794 | 95.0% |
| Singular Genomics Systems, Inc. | 54,919 | NEW |
| SEM | 53,717 | NEW |
| SpringWorks Therapeutics, Inc. | 42,981 | 9.4% |
| LENZ | 33,997 | NEW |
| GHRS | 31,045 | NEW |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
24,135
(0.2% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type | Discretion | Other Manager | Sole | Shared | None |
|---|
Other Managers
| Num | Name | File Number |
|---|---|---|
| 1 | ORBIMED CAPITAL LLC | 028-10410 |